Medtronic Spins Off MiniMed via Oversubscribed, Second-Largest Medtech IPO to Nasdaq
Medtronic launched an oversubscribed IPO for its MiniMed Group, raising undisclosed proceeds in the second-largest offering in Medtech history as MMED began trading today on Nasdaq Global Select Market. The spin-off establishes MiniMed as an agile standalone entity and frees Medtronic to reallocate capital toward core value-creation initiatives.
1. MiniMed Begins Trading
MiniMed Group began trading under ticker symbol MMED on the Nasdaq Global Select Market following an initial public offering that was oversubscribed and ranked as the second-largest IPO in Medtech history.
2. Offering Details
The IPO attracted strong investor demand, resulting in oversubscription, though Medtronic has not disclosed the exact capital raised; the listing enhances MiniMed's financial flexibility and visibility in the diabetes device segment.
3. Strategic Impact on Medtronic
By spinning off MiniMed, Medtronic aims to focus resources on core businesses, improve capital allocation for long-term value creation, and allow the diabetes unit to operate with greater agility as an independent entity.